Clinical Trial Update: Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 study of arzoxifene hydrochloride in women with metastatic refractory ovarian cancer or primary peritoneal cancer; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Arzoxifene hydrochloride (arzoxifene hydrochloride)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer | Phase 2 | Status: COMPLETED